Cannabis Science Inc (OTCMKTS:CBIS) a U.S. firm specializing in the advancement of CBD-based drugs reported that it has invested in the RD of new CBD-based drugs to cure Chronic Obstructive Pulmonary Disease and Asthma. As per the latest data, in the U.S. alone more than 15 million people suffer from COPD, and more than 25 million are diagnosed with Asthma.
More institutions continue to note that Cannabis-derived drugs are indeed an effective and promising tool to fight pulmonary ailments, and that there is a paucity of delivery systems for CBD medications. They have positioned CBIS at the major side of the RD of delivery mechanisms of these medications. The CBIS MDI is showing to be effective and is in demand as a tool in combating pulmonary diseases.
COPD and Asthma have different stages of severity needing different course of treatment, and identifying this the Cannabis Science Research and Development